Drug News

Global Artemisinin Combination Therapy Market Report 2023 – Growing R&D of New Artemisinin Combination Therapies

The Global Artemisinin Combination Therapy Market has witnessed significant growth, with a steady rise in demand, driven by escalating research and development activities focused on introducing new Artemisinin Combination Therapies.

This comprehensive market analysis, titled “Global Artemisinin Combination Therapy Market (2022-2027) by Combination Therapy Type, and Geography, Competitive Analysis,” provides valuable insights into market dynamics, trends, and key players, offering a detailed assessment of the industry landscape.

Market Overview:

The Global Artemisinin Combination Therapy Market, valued at USD 520.94 million in 2022, is projected to reach USD 771.12 million by 2027, registering a Compound Annual Growth Rate (CAGR) of 8.16%. The market is segmented based on Combination Therapy Type and Geography. Key combination therapy types include Artemether-Lumefantrine, Artesunate-Amodiaquine, and Others. Geographically, the market is classified into Americas, Europe, Middle-East & Africa, and Asia-Pacific.

Market Dynamics:


•          Rising Demand for Artemisinin Combination Therapy: Increasing prevalence of malaria and the effectiveness of Artemisinin Combination Therapy (ACT) in treating the disease contribute to growing demand.

•          Rising Government Initiatives: Supportive government initiatives and programs aimed at combating malaria fuel market growth.

•          Growing Malaria Endemic: The global prevalence of malaria, especially in regions like sub-Saharan Africa, drives the demand for effective treatment options.


•          High Cost of Artemisinin Combination Therapy Courses: The relatively high cost of ACT courses may limit accessibility, particularly in resource-constrained regions.


•          Growing R&D of New Artemisinin Combination Therapies: Increased research and development activities present opportunities for the introduction of innovative therapies, potentially addressing existing limitations.


•          Side Effects Associated with ACT: Adverse effects associated with Artemisinin Combination Therapy pose challenges to widespread adoption.

•          Lack of Availability of Raw Materials: Limited availability of raw materials for ACT production adds to market challenges.

Company Profiles:

The report provides a comprehensive analysis of key market players, including financial performance, recent developments, and competitive scenarios. Notable companies covered include Cipla, KPC Pharmaceuticals, Guilin Pharmaceutical, Sanofi, Novartis, Shanghai Fosun Pharmaceutical, Denk Pharma, Ipca Laboratories, Ajanta Pharma, Bliss GVS Pharma, and Macleods Pharmaceuticals.

Report Highlights:

•          Comprehensive market analysis, encompassing parent industry

•          Examination of crucial market dynamics and trends

•          Detailed segmentation based on value and volume

•          Financial performance analysis of key players

•          In-depth insights into recent developments and competitive scenarios

•          Recommendations for companies to strengthen market foothold

Key Report Benefits:

•          Comprehensive evaluation of the Global Artemisinin Combination Therapy Market

•          In-depth qualitative analysis with verifiable data from authentic sources

•          Projections based on proven research methodologies

•          Extensive primary and secondary research, including interviews, surveys, and industry observation

•          Market analysis using Porter’s 5 forces model and the Ansoff Matrix

•          Consideration of the impact of Covid-19 on the market

•          Exploration of the regulatory scenario, discussing major regulatory bodies and rules imposed across geographies

•          Competitive analysis using Positioning Quadrants, the analyst’s competitive positioning tool.


Joan David-Leonhard

Joan David Leonhard is a recent Pharm.D graduate with a strong passion for the pharmaceutical industry and a particular interest in pharmaceutical media and communication. Her brief internship experience includes roles in pharmacy where she built strong patient-pharmacist relationships and a pharmaceutical media internship where she actively contributed to drug information articles, blog posts, social media engagement, and various media projects.
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker